6-{3-[(2-bromophenyl)oxy]azetidin-1-yl}pyridazine-3-carbohydrazide | 960492-75-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 6-{3-[(2-bromophenyl)oxy]azetidin-1-yl}pyridazine-3-carbohydrazide
• 英文别名: 6-[3-(2-bromophenoxy)azetidin-1-yl]pyridazine-3-carbohydrazide
• CAS: 960492-75-5
• 化学式: C₁₄H₁₄BrN₅O₂
• 分子量: 364.201
• InChiKey: IRRCJOIQQWAFPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  93.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-{3-[(2-bromophenyl)oxy]azetidin-1-yl}pyridazine-3-carbohydrazide 在 伯吉斯试剂 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 1.5h， 生成 [5-(6-{3-[(2-bromophenyl)oxy]azetidin-1-yl}pyridazin-3-yl)-1,3,4-oxadiazol-2-yl]methyl acetate
  参考文献：
  名称：

  WO2007/143823

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氯哒嗪-3-甲酸甲酯 在 potassium carbonate 、 肼 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 22.0h， 生成 6-{3-[(2-bromophenyl)oxy]azetidin-1-yl}pyridazine-3-carbohydrazide
  参考文献：
  名称：

  WO2007/143823

  摘要：

  公开号：

文献信息

• Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
  申请人：Isabel Elise

  公开号：US20090170828A1

  公开（公告）日：2009-07-02

  Azetidine derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; liver steatosis; and non-alcoholic steatohepatitis. (I)

  结构式I的氮杂环丙烷衍生物是选择性抑制硬脂酰辅酶A delta-9去饱和酶(SCD1)的化合物，相对于其他已知的硬脂酰辅酶A去饱和酶。本发明的化合物可用于预防和治疗与异常脂质合成和代谢相关的疾病，包括心血管疾病；动脉粥样硬化；肥胖症；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗；肝脂肪变性和非酒精性脂肪性肝炎。
• Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors
  作者：Elise Isabel、David A. Powell、W. Cameron Black、Chi-Chung Chan、Sheldon Crane、Robert Gordon、Jocelyne Guay、Sebastien Guiral、Zheng Huang、Joël Robichaud、Kathryn Skorey、Paul Tawa、Lijing Xu、Lei Zhang、Renata Oballa

  DOI：10.1016/j.bmcl.2010.10.107

  日期：2011.1

  Potent and orally bioavailable SCD inhibitors built on an azetidinyl pyridazine scaffold were identified. In a one-month gDIO mouse model of obesity, we demonstrated that there was no therapeutic index even at low doses; efficacy in preventing weight gain tracked closely with skin and eye adverse events. This was attributed to the local SCD inhibition in these tissues as a consequence of the broad tissue distribution observed in mice for this class of compounds. The search for new structural scaffolds which may display a different tissue distribution was initiated. In preparation for an HTS campaign, a radiolabeled azetidinyl pyridazine displaying low non-specific binding in the scintillation proximity assay was prepared. (c) 2010 Elsevier Ltd. All rights reserved.
• EP2032566A4
  申请人：——

  公开号：EP2032566A4

  公开（公告）日：2009-07-08
• AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Merck Frosst Canada Ltd.

  公开号：EP2032566A1

  公开（公告）日：2009-03-11
• [EN] AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] DÉRIVÉS D'AZÉTIDINE COMME INHIBITEURS DE LA STÉAROYL-COENZYME A DELTA-9 DÉSATURASE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2007143823A1

  公开（公告）日：2007-12-21

  [EN] Azetidine derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; liver steatosis; and non-alcoholic steatohepatitis. (I)
  [FR] L'invention concerne des dérivés d'azétidine de formule structurelle I qui sont des inhibiteurs sélectifs de la stéaroyl-coenzyme A delta-9 désaturase (SCD1) relativement à d'autres stéaroyl-coenzyme A delta-9 désaturases connues. Les composés de la présente invention sont utiles pour la prévention et le traitement d'états liés à une synthèse et à un métabolisme lipidiques anormaux, y compris les maladies cardiovasculaires, l'athérosclérose, l'obésité, le diabète, les maladies neurologiques, le syndrome métabolique, la résistance à l'insuline, la stéatose hépatique et la stéatohépatite non alcoolique. (I)